These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 22516155)

  • 1. Combined intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation.
    Lee MY; Kim KS; Lee WK
    Am J Ophthalmol; 2012 May; 153(5):1004-5; author reply 1005. PubMed ID: 22516155
    [No Abstract]   [Full Text] [Related]  

  • 2. Combined intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation.
    Saito M; Iida T; Kano M
    Am J Ophthalmol; 2012 Mar; 153(3):504-514.e1. PubMed ID: 22078902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination treatment of photodynamic therapy with verteporfin and intravitreal ranibizumab in patients with retinal angiomatous proliferation.
    Seidel G; Werner C; Weger M; Steinbrugger I; Haas A
    Acta Ophthalmol; 2013 Sep; 91(6):e482-5. PubMed ID: 23786546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term results of intravitreal ranibizumab, intravitreal ranibizumab with photodynamic therapy, and intravitreal triamcinolone with photodynamic therapy for the treatment of retinal angiomatous proliferation.
    Rouvas AA; Chatziralli IP; Theodossiadis PG; Moschos MM; Kotsolis AI; Ladas ID
    Retina; 2012 Jun; 32(6):1181-9. PubMed ID: 22466469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subfoveal choroidal thickness changes after intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation.
    Maruko I; Iida T; Oyamada H; Sugano Y; Saito M; Sekiryu T
    Retina; 2015 Apr; 35(4):648-54. PubMed ID: 25627088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ranibizumab in retinal angiomatous proliferation (RAP): influence of RAP stage on visual outcome.
    Reche-Frutos J; Calvo-Gonzalez C; Pérez-Trigo S; Fernandez-Perez C; Donate-Lopez J; Garcia-Feijoo J
    Eur J Ophthalmol; 2011; 21(6):783-8. PubMed ID: 21484755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Treat and extend" dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation.
    Engelbert M; Zweifel SA; Freund KB
    Retina; 2009; 29(10):1424-31. PubMed ID: 19898180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot study on the combination treatment of reduced-fluence photodynamic therapy, intravitreal ranibizumab, intravitreal dexamethasone and oral minocycline for neovascular age-related macular degeneration.
    Sivaprasad S; Patra S; DaCosta J; Adewoyin T; Shona O; Pearce E; Chong NV
    Ophthalmologica; 2011; 225(4):200-6. PubMed ID: 21293163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and risk factors for macular hemorrhage following intravitreal ranibizumab injection for neovascular age-related macular degeneration.
    Moon SW; Oh J; Yu HG; Cho HY; Song SJ
    J Ocul Pharmacol Ther; 2013; 29(6):556-9. PubMed ID: 23480269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years.
    Spielberg L; Leys A
    Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):943-56. PubMed ID: 20204659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of intravitreal triamcinolone acetonide with photodynamic therapy and intravitreal bevacizumab with photodynamic therapy for retinal angiomatous proliferation.
    Saito M; Shiragami C; Shiraga F; Kano M; Iida T
    Am J Ophthalmol; 2010 Mar; 149(3):472-81.e1. PubMed ID: 20053392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for geographic atrophy after intravitreal ranibizumab injections for retinal angiomatous proliferation.
    Cho HJ; Yoo SG; Kim HS; Kim JH; Kim CG; Lee TG; Kim JW
    Am J Ophthalmol; 2015 Feb; 159(2):285-92.e1. PubMed ID: 25447115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal anti-VEGF therapy blocks inflammatory cell infiltration and re-entry into the circulation in retinal angiogenesis.
    Nakao S; Arima M; Ishikawa K; Kohno R; Kawahara S; Miyazaki M; Yoshida S; Enaida H; Hafezi-Moghadam A; Kono T; Ishibashi T
    Invest Ophthalmol Vis Sci; 2012 Jun; 53(7):4323-8. PubMed ID: 22661475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance?
    Binder S
    Br J Ophthalmol; 2012 Jan; 96(1):1-2. PubMed ID: 22157632
    [No Abstract]   [Full Text] [Related]  

  • 15. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration.
    Krebs I; Schmetterer L; Boltz A; Told R; Vécsei-Marlovits V; Egger S; Schönherr U; Haas A; Ansari-Shahrezaei S; Binder S;
    Br J Ophthalmol; 2013 Mar; 97(3):266-71. PubMed ID: 23292928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term effects of a single intravitreal bevacizumab injection on retinal vessel calibre.
    Tatlipinar S; Dinç UA; Yenerel NM; Görgün E
    Clin Exp Optom; 2012 Jan; 95(1):94-8. PubMed ID: 21954975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration.
    Landa G; Amde W; Doshi V; Ali A; McGevna L; Gentile RC; Muldoon TO; Walsh JB; Rosen RB
    Ophthalmologica; 2009; 223(6):370-5. PubMed ID: 19590252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two-year results of combined intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation.
    Saito M; Iida T; Kano M; Itagaki K
    Jpn J Ophthalmol; 2016 Jan; 60(1):42-50. PubMed ID: 26498642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The MANTA 1-year results: the anti-VEGF debate continues.
    Ehlers JP
    Br J Ophthalmol; 2013 Mar; 97(3):248-50. PubMed ID: 23087420
    [No Abstract]   [Full Text] [Related]  

  • 20. Stroke rates after introduction of vascular endothelial growth factor inhibitors for macular degeneration: a time series analysis.
    Campbell RJ; Bell CM; Paterson JM; Bronskill SE; Moineddin R; Whitehead M; Gill SS
    Ophthalmology; 2012 Aug; 119(8):1604-8. PubMed ID: 22717458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.